Marie Sklodowska-Curie Fellowships are European research grants available to researchers regardless of their nationality or field of research. The general objective is to stimulate the mobility of researchers.
margot.beereboom@fwo.be
+32 2 550 15 76
Marie Sklodowska-Curie Fellowships are European research grants available to researchers regardless of their nationality or field of research. In addition to generous research funding scientists have the possibility to gain experience abroad and in the private sector, and to complete their training with competences or disciplines useful for their careers.
The Marie Sklodowska-Curie programme aims to foster innovation, research-business cooperation and also includes a strong international component based on the principle of mobility.
The MSCA provides funding for all stages of research careers, being doctoral candidates or highly experienced researchers and by ensuring good working conditions and work/life balance for the researchers.
The programme is open to all fields of research and innovation, from fundamental research to market take-up and innovation services. Furthermore, it also encourages mobility between the different sectors (universities, research centres, and companies), disciplines and countries.
There are five types of Marie Sklodowska-Curie Actions:
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.